Original Article

Dosimetric impacts on skin toxicity for patients using topical agents and dressings during radiotherapy

Karen Tse¹, Lyndon Morley¹, Angela Cashell¹,², Annette Sperduti¹, Maureen McQuestion¹,³, James C. L. Chow¹,²

¹Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, ²Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada, ³Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada

(Received 5 March 2016; revised 2 May 2016; accepted 3 May 2016; first published online 10 June 2016)

Abstract

Background and purpose: Skin care practices for radiotherapy patients are complicated by dosimetric concerns. This study measures the effect on skin dose of various topical agents and dressings.

Materials and methods: Superficial doses were measured under 17 topical agents and dressings and three clinical materials for reference. Dose was measured using a MOSFET detector under a 1 mm polymethyl methacrylate slab, with 6 MV photon beams at 100 cm source to surface distance.

Results: Relative skin dose under reference materials was 128% (thermoplastic mask), 158% (5 mm bolus) and 171% (10 mm bolus). Under a realistic application of topical agent (0.5 mm), relative skin doses were 106–111%. All dry dressings yielded relative dose of ≤111%; two wet dressings yielded higher relative doses (133 and 141%).

Conclusions: Under clinically relevant conditions, no cream, gel or dry dressing increased the skin dose beyond that seen with a thermoplastic mask. Dressings soaked with water produced less skin dose than 5 mm bolus. This may be unacceptable if wet dressings are in place for the majority of the treatment course. Our results suggest that skin care practices should not be limited by dosimetric concerns when using a 6 MV photon beam.

Keywords: medical dosimetry; patient education; patient teaching; radiation skin dose; radiation therapy; self-care instructions; side-effect management; skin care during radiation therapy

INTRODUCTION

Acute radiotherapy (RT) side effects involving the skin include pain, discomfort, irritation, itching and burning.1–3 Typical skin reactions begin with erythema and may progress through stages of dry desquamation, moist desquamation and ulceration.1–3 Skin reactions are patient specific and factors affecting the onset and severity of skin reactions are treatment and patient dependent. Treatment associated factors include target location, beam type, energy and technique, fraction size, fraction and total dose, and use of dose modifying materials such as bolus, wedges
and filters. Patient related factors may include age, concurrent therapy (e.g., chemotherapy) and condition of the skin which may be affected by previous surgery or disease, patient’s typical skin routine and previous sun exposure.1,3

Oncology staff provide information and interventions to manage these acute effects. Information includes instructions on maintaining skin cleanliness and integrity preventatively. Interventions may include medicated topical agents and dressings to manage discomfort, avoid infection and promote healing.1,4,5

Optimal prevention and management of skin reactions in RT is complicated by wide-spread concerns among professionals in the field that applying products on the skin during radiation delivery will increase skin dose and toxicity.6–8 Patient education often includes teaching patients to avoid applying creams, lotions and deodorants on the skin before RT due to fear of increasing the severity of skin reactions.2,9 Informal surveys in our department revealed that staff members routinely instruct patients to avoid applying any skin products 1–2 hours before treatment or to wipe off residual creams before treatment delivery, in spite of any institutional practice guidelines recommending these restrictions. The use of dressings or other topical products in wound care by nursing staff was also restricted during the course of treatment. Staff indicated this was a common practice learned primarily from colleagues although it was not known whether or not this was evidence based. One study6 discovered that some American and Canadian cancer centres provide no restrictions to patients applying topical agents to the skin, while others gave specific time restrictions and some centres instructed patients to completely avoid applying topical agents to the skin at any time before RT. Only one institution was found to reference their practice using evidence based guidelines.5

Variations in skin care management instructions can be distressing and confusing to patients, especially if the information is conflicting or complicated.2,5,7 Instructions for applying moisturiser regularly combined with restrictions based on complicated radiation physics principles may not be easy for patients to interpret. Consultation with patients in our institution found that patients may alter their skin care regimen in unintended ways in the face of this complicated and apparently conflicting information. Patients are less confused and have better self-care adherence when provided with consistent and straightforward care instructions.10

Restrictions in the management of skin toxicity appear to be wide-spread and primarily based on two main concerns:11

1. An increase of dose due to higher photon interactions from the metallic component of the creams.
2. A bolus effect created by an increased layer added to the surface of the skin, leading to an increased skin reaction.

The effect on skin dose of moisturisers and other commonly used products has been reported in several studies. One such study5 determined that a clinically meaningful increase in skin dose required at least 0.7 mm of product on the skin during treatment delivery under the least favourable conditions tested. A realistic application of such products is closer to 0.3 mm.12 Skin care instructions and wound management practices were simplified and less restricted in our institution following these results.5 An early but sentinel study by Burch et al.8 investigated the surface dose on 15 different products using a Markus type parallel plate ionisation chamber in a polystyrene phantom (six deodorants, two powders and seven lotions) and found no large increase in surface dose. The study did not specify which products were tested, but indicated that the lotions were safe for use during RT from a dose to skin perspective.8

Dressings are potentially much thicker and variable in density and material components compared with oil or water-based creams. A survey was done with 18 oncology centres in Canada13 on their policy of removing wound dressings during RT. Results showed that half of the surveyed centres would leave the dressings in place during treatment, while the remaining centres would remove the dressings. These decisions were primarily based on individual evaluation and personal practices rather than department policies or evidence.
There are inconsistencies reported in the literature with respect to the standard of care of when to use topical agents and dressings during RT. Several studies measure dose under such products, however interpreting the results of these studies requires consideration of the different approaches to measuring skin dose, the different products tested, and the different beam parameters used. Measurement of superficial dose can be challenging and may be approached using a variety of instruments and at varying depths to approximate dose to skin epithelium. Several studies use a variety of measurement techniques at different depths. The epithelial layer varies according to properties such as location, age, skin condition and other factors. In one particular study, the depth of the epidermis was measured between 64 and 123 µm, and another study measured the epidermis to be 74.9–96.5 µm. Care must be taken in interpreting and comparing such results and relating them to other relevant clinical scenarios. In practice, the most important depth for skin reactions will vary by skin type, patient factors, and area of the body under consideration. Understanding the dosimetric impact of various surface materials is improved when the dose impacts are compared to other relevant scenarios for which clinicians have an established frame of reference. The relative dose increase at other reference depths will be approximately proportional given the shape of photon depth dose curves in the build-up region.

This study aims to build on previous work by measuring relative skin dose enhancement for a range of products commonly used in RT. These include products potentially underutilised due to dose concerns, and products containing high atomic number materials that appear to raise concern among practitioners. Dressings in a dry and wet state will also be studied. These relative doses are compared, under the same conditions, to skin dose enhancement from relatable clinical scenarios such as under thermoplastic immobilisation material and Superflab bolus; the purpose of this study is not to determine the absolute dose to the epidermis. Conclusions should inform clinical practice regarding patient education, preventative care instructions, and the management of skin changes during RT.

**MATERIALS AND METHODS**

**Products tested**

The skin products used in the study are shown in Table 1. Inclusion of products in this study is neither an endorsement nor claim of efficacy.

<table>
<thead>
<tr>
<th>Product</th>
<th>Manufacturer</th>
<th>Indication</th>
<th>Rationale for inclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proshield Plus Skin Protectant</td>
<td>Healthpoint Inc.</td>
<td>Moist desquamation</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>(SBBC)</td>
<td></td>
<td>Erythema and dry desquamation</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>Glaxol Base Cream™ (water-based moisturiser)</td>
<td>Wellspring Pharmaceutical Canada Corp.*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flamazine 1%</td>
<td>Smith &amp; Nephew</td>
<td>Antimicrobial</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>SPF 30 lotion</td>
<td>Rexall®</td>
<td>Sun protection</td>
<td>Used by patients. Has SPF rating</td>
</tr>
<tr>
<td>Water-based SPF 15 moisturiser</td>
<td>Aveeno®</td>
<td>Erythema and dry desquamation with sun protection</td>
<td>Used by patients. Has SPF rating</td>
</tr>
<tr>
<td>Hydrocortisone 1%</td>
<td>GlaxoSmithKline Inc.</td>
<td>Alleviate anti-inflammatory response (pruritus)</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>Polysporin® Ointment</td>
<td>Polysporin®</td>
<td>Anti-biotic cream</td>
<td>Used by patients</td>
</tr>
<tr>
<td>Desitin® (zinc 40%)</td>
<td>Desitin®</td>
<td>Diaper rash</td>
<td>High zinc component (40%)</td>
</tr>
<tr>
<td>Zincofax</td>
<td>Zincofax</td>
<td>Diaper rash</td>
<td>Zinc component (15%)</td>
</tr>
<tr>
<td>Silvasorb® Gel</td>
<td>Medline Industries Inc.</td>
<td>Anti-microbial gel</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>Aloe Vera Gel</td>
<td>Fruit of the Earth®</td>
<td>Anti-inflammatory and antibacterial wound care</td>
<td>Used in RT departments</td>
</tr>
<tr>
<td>Medihoney® Derma Gel</td>
<td>Medihoney®</td>
<td></td>
<td>Active Leptospermum Honey</td>
</tr>
</tbody>
</table>

**Abbreviations:** SBBC, silicone-based barrier cream; RT, radiotherapy; SPF, sun protection factor.

---

[Table 1. List of creams, lotions, and gels used in this study]
Products were chosen because they are commonly used in RT practice, represent a general class of product commonly selected by patients based on our experience, or because they contain high atomic number components (e.g., zinc, iodine and silver). Products selected were not intended to be exhaustive, but were intended to cover a spectrum of materials covering the types of products practitioners may encounter in clinical practice.

Dressings used in the study are shown in Table 2. Absorbent materials were tested under both dry and wet conditions to test situations where the dressing may be present over a dry wound or a heavily exudative wound that may soak the dressing material over time.

**Beam geometry**

The effect of varying photon field size and beam obliquity was previously studied.5 A single beam geometry was therefore selected for this study and can be related to other conditions tested previously.5 A photon beam energy of 6 MV was selected since it was the lowest photon beam energy readily available and lower MV energies are relatively uncommon. Higher photon beam energies are more sparing and would therefore yield less relative dose increase with products on the surface. Moreover, 6 MV photon beams are currently the most widely used for intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). A $10 \times 10 \text{cm}^2$ field size was used to simulate large open fields; smaller fields with less scatter contribution would have less relative dose increase with products on the surface as shown in the previous study.5

**Comparative clinical scenarios**

Any additional material on the surface will produce superficial dose enhancement. The clinical relevance of such increase must be determined by comparing to other relevant clinical scenarios. Most centres consider the increased scatter dose arising from thermoplastic immobilisation material on the surface on the order of 18%18 to 28%5 to be acceptable.19 On the other end of the spectrum, 5 mm Superflab™ (Mick Radio-Nuclear Instruments Inc.) bolus is commonly used to intentionally increase skin dose. Measurements were therefore taken in the presence of one layer of thermoplastic mask, 5 mm Superflab™ bolus and 10 mm Superflab™ bolus for comparison.

**Metal oxide semiconductor field effect transistor (MOSFET) measurements**

Figure 1 shows the experimental setup of our dosimetric measurement. The same methodology was used as the study by Morley et al.5 A MOSFET detector (TN-1002RD; Thomson and Nielsen Electronic, Ottawa, ON, Canada) was located on top of the 5 mm Superflab™ bolus, and was centred at the central beam axis

![Table 2. List of dressings used in this study](https://www.cambridge.org/core/terms. doi:10.1017/S1460396916000285)
Advantages of using a MOSFET detector include its small size, accuracy at low dose, immediate reuse and its ability to record dose history. All MOSFET detectors used in this study were calibrated using our local standard ionisation chamber and electrometer.

The density of bolus is equal to 1.02 g/cm³ and is made of tissue-equivalent Superflab™ plastic. In Figure 1, the MOSFET detector was covered by a 1 mm polymethyl methacrylate (PMMA) layer mimicking the approximate depth of epithelium and critical dermal tissues. The most clinically relevant skin depth depends on properties such as location, age, skin condition and other factors; such a specific clinical depth is not required to achieve the purposes of this study. Skin products were applied on the surface of the PMMA layer irradiated by the 6 MV photon beam, produced by the Varian TrueBEAM linear accelerator (Varian Medical Systems). A Solid Water slab (SW-457; Gammex RMI, Middleton, WI, USA) of 25 × 25 × 5 cm³ was placed underneath the bolus to provide adequate backscatter. The source-to-surface distance (SSD) was set to 100 cm at the PMMA surface and the field size of the 6 MV photon beam was equal to 10 × 10 cm². The linear accelerator was calibrated to deliver 1 cGy/monitor unit (MU) at the depth of the maximum dose (1.5 cm). In this study, 100 MUs were given in each measurement with a dose rate of 600 MU/minute. Repeat measurements were obtained and averaged for each experimental condition.

**Experimental setup**

Plastic wells with dimensions of 12 × 12 × 0.15 cm³ were created and filled with cream, lotion or gel. There was an effort to create a uniform and even layer within the well. The thickness of topical agent was noted to be much more than normally observed on a patient’s skin and thicker than a patient would likely be able to maintain for any length of time. The dose implications of thinner applications of these products were estimated to be proportional to the thickness for the tested geometry based on a previous study under the same conditions. Single layer dressings were laid flat, ensuring the dressing covered the 10 × 10 cm² radiation field by at least 2 cm on all sides. Dressings were tested in both wet and dry states given that clinical applications may result in wound exudate accumulating in the dressings under some conditions. Wet dressings were prepared by soaking the dressings in water, laying them flat, and allowing excess water to drain off. Wet dressings were considered comparable to dressings applied to a moist wound long enough to be maximally saturated with wound exudate (including serum, fibrin and blood cells).

**RESULTS**

Repeatability of the MOSFET measurements was found to be the same as in previous work. The relative dose under the creams, lotions, and gels at specified thickness is shown in Figure 2. Relative dose was calculated by dividing the tested agents’ dose by the dose of the control (no tested agent).
Relative skin dose under reference materials was 128% (thermoplastic mask), 158% (5 mm bolus) and 171% (10 mm bolus). At maximum tested thickness of 1.5 mm, the relative dose under all topical agents did not exceed that of thermoplastic mask with the exception of Desitin® zinc 40% (133%) and Silvasorb® gel (129%). All products produced much less skin dose than the thermoplastic mask for more realistic application thickness (0.5 mm). The relative dose versus dressings graph is shown in Figure 3. Mepilex® lite (wet) and Mepilex® Ag transfer (wet) exhibited a relative dose greater than the dose under the thermoplastic mask (133 and 141%, respectively) but not above the bolus references. All other tested dressings yielded relative doses under 111%.

DISCUSSION

Most centres generally consider the dose under a thermoplastic mask for treatments of head and neck cancers to be acceptable, therefore it seems reasonable to accept similar relative doses under products used to prevent or manage skin reactions from treatment. Relative doses <128% should therefore be acceptable, particularly considering that the tested products are unlikely to be present for every treatment fraction, unlike mask material or bolus. None of the tested products were close to producing dose enhancement comparable to that of 5 mm bolus.

The relative dose versus creams, lotions and gels were plotted against the thickness of the topical agents. Although the tested thickness of the topical agents was 1.5 mm, information from previous work including Monte Carlo simulation and physical measurements under similar conditions allowed extrapolation for 0.5 and 1 mm thicknesses.

A 1.5 mm application of cream, lotion or gel appears to be an excessive amount to expect a patient to apply; the prepared 1.5 mm samples demonstrated that this volume of product would drip down any non-horizontal surface. This thickness was used for dose measurement to assist with creating reproducible testing conditions. Other studies did not measure the thickness of the topical agent, but relied on applying a ‘normal application’ that a patient would routinely apply on their skin. A realistic amount of moisturiser is around 0.3 mm. In Figure 2, none of the topical agents exceeded the dose under the thermoplastic mask if the thickness was 0.5 mm. Even topical applications were plotted against the thickness of the topical agents. Although the tested thickness of the topical agents was 1.5 mm, information from previous work including Monte Carlo simulation and physical measurements under similar conditions allowed extrapolation for 0.5 and 1 mm thicknesses.
agents with high atomic number constituents (Desitin® zinc 40% and Zincofax® 15%) did not have a higher relative dose compared with the thermoplastic mask at 1 mm thickness. These products are not commonly used by RT patients; their inclusion was to address concerns expressed by some clinicians for the potential bolus effect due to metallic components of topical agents.

Figure 3 represents the relative dose under various dressings. Mepilex® lite and Mepilex® Ag transfer were tested in wet and dry simulations. All dry dressings produced less dose enhancement compared with the thermoplastic mask. In real applications, it is unlikely that dressings would be maximally saturated with fluid for any significant portion of a RT treatment course. Wet dressings did produce a dose enhancement greater than the thermoplastic mask (Mepilex® Lite, 133% and Mepilex® Ag transfer, 142%) but well under the dose for 5 mm and 10 mm Superflab™ bolus. These dose enhancements are not of a concern if the dressing is partially wet, present for only a portion of RT fractions, or both. Clinical experts in this field state that daily removal of dressings before treatment is not ideal due to factors such as pain associated with the removal of the dressings and the cost of supplies associated with repeated removal of the dressings.13 In cases where RT is directed at an existing wound with large amounts of exudate or bleeding, dose to the wound may in fact be desirable.

This study used a single beam energy (6 MV), field size (10 × 10 cm²) and geometry (directly incident beam). Extrapolation to other scenarios relies on previous work testing other configurations. The dose implications of the tested products may be higher for lower energy beams, notably for 4 MV or Cobalt 60 sources which are used in some centres. Higher energy beams would result in less superficial dose enhancement. Smaller field sizes, including highly segmented beams such as found in most IMRT and VMAT treatment plans, have lower scatter factors and would therefore result in less dose enhancement. This study did not examine any medical considerations of using these products during RT, such as the effectiveness of these products in preventing, limiting or managing side effects.

CONCLUSIONS

None of the tested products produced a concerning skin dose enhancement under conditions which could reasonably be expected to occur in clinical practice. Very saturated, and absorbent dressings

Figure 3. Relative dose under dressings. All tested dressings (except for Mepilex® lite (wet) and Mepilex® Ag transfer (wet)) yielded relative dose under 111%. Wet Mepilex® lite and wet Mepilex® Ag transfer had a relative dose greater than the dose under the thermoplastic mask (133 and 141%, respectively) but not above the bolus references.
may produce unacceptable skin dose enhancement if they are present for the majority of the treatment course. This conclusion holds for products containing zinc, iodine, silver and those with a sun protection factor. There is no evidence supporting restrictions on the use of these or similar skin products during MV photon beam RT. In this era of new technologies and techniques, medical rationales for designing skin care instructions and wound care management should be pursued to formulate best practice guidelines surrounding usage of topical agents and dressings during RT.

Acknowledgements

Thanks to Tara Rosewall who has provided her writing assistance and support for publication.

Financial support

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflicts of Interest

None.

References